Loading clinical trials...

Efficacy of QAX576 in Asthma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Efficacy of QAX576 in Asthma

A Multi-center, Randomized, Double Blind, Placebo-controlled, 'add-on' Study to Investigate the Efficacy and Safety of 24 Weeks Intravenous Treatment With QAX576 in Patients (≥18-75 Years) With Persistent Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting β2-agonists

NCT01130064•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female patients
•Female patients must be surgically sterilized or postmenopausal
•Male patients must use two forms of contraception
•Body mass index must be between 18 and 39 kg/m2
•Diagnosis of asthma for at least one year, which is not adequately controlled by inhaled corticosteroids and long acting beta-2 agonists

Exclusion Criteria

•Smoking history \>10 pack-years
•Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
•Patients who have experienced a severe asthma attack/exacerbation requiring systemic corticosteroids or an increase in maintenance doses, within 6 weeks of screening
•Patients who have had a respiratory tract infection within 6 weeks prior to screening
•History of schistosomiasis, within 6 months of screening, or traveling to a country endemic with schistosomiasis within 6 months of completing the study

Locations (52)

Novartis Investigative Site

Phoenix, Arizona, United States

Novartis Investigative Site

Huntington Beach, California, United States

Novartis Investigative Site

Owensboro, Kentucky, United States

Novartis Investigative Site

Wheaton, Maryland, United States

Novartis Investigative Site

Minneapolis, Minnesota, United States

Novartis Investigative Site

St Louis, Missouri, United States

Novartis Investigative Site

Las Vegas, Nevada, United States

Novartis Investigative Site

Marion, Ohio, United States

Novartis Investigative Site

Charleston, South Carolina, United States

Novartis Investigative Site

Summerville, South Carolina, United States

Key Dates

Start Date

May 1, 2010

Primary Completion Date

April 1, 2012

Completion Date

April 1, 2012

Last Updated

December 19, 2020

Enrollment

259

ACTUAL participants

Conditions

Asthma

Interventions

QAX576

BIOLOGICAL

Placebo

DRUG

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173

Asthma

View study

RECRUITING

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of QAX576 in Asthma

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma